EFIKASI DAN KEAMANAN KOMBINASI BROADLY NEUTRALIZING ANTIBODIES UNTUK MENEKAN KADAR VIREMIA PADA PASIEN HUMAN IMMUNODEFICIENCY VIRUS TIPE 1: SEBUAH TINJAUAN LITERATUR
Sebuah Tinjauan Literatur
DOI:
https://doi.org/10.53366/jimki.v11i2.796Keywords:
HIV-1, bNAbs combinations, virology, therapyAbstract
Background: Human Immunodeficiency Virus type 1 (HIV-1) remains a global health challenge with persistently high infection and mortality rates. Current antiretroviral therapy has not been able to completely eliminate the virus, highlighting the need for long-term alternative treatment strategies. The combination of broadly neutralizing antibodies (bNAbs) has emerged as a promising approach to suppress viremia and improve long-term control of HIV-1.
Methods: This literature review was conducted by searching scientific articles in the PubMed and ScienceDirect databases using specific keywords related to bNAbs and HIV-1. Article selection was based on predefined inclusion and exclusion criteria, resulting in seven clinical trial articles for further analysis.
Discussion: Current evidence shows that combination bNAbs offer improved efficacy and safety in addressing the genetic diversity of HIV-1 and preventing the emergence of resistance. The use of double, triple, and quadruple bNAb combinations has been shown to broaden viral neutralization and optimize long-term plasma viremia control. Favorable safety profiles in clinical trials support the potential of bNAbs as a promising long-term therapeutic candidate. However, most included studies had limited sample sizes and did not assess the long-term effects of the therapy.
Conclusion: Combination bNAb therapy has the potential to become an effective and sustainable strategy in the management of HIV-1. Larger-scale studies are needed to strengthen clinical evidence and optimize its implementation.
Keywords: HIV-1, bNAbs combinations, virology, therapy
References
1. Govender RD, Hashim MJ, Khan MA, Mustafa H, Khan G. Global Epidemiology of HIV/AIDS: A Resurgence in North America and Europe. J Epidemiol Glob Health. 2021 Sep;11(3):296–301.
2. WHO. HIV data and statistics [Internet]. 2024 [cited 2024 Jul 5]. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics
3. Swinkels HM, Justiz Vaillant AA, Nguyen AD, Gulick PG. HIV and AIDS. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Jul 5]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK534860/
4. Wong K, Nguyen J, Blair L, Banjanin M, Grewal B, Bowman S, et al. Pathogenesis of Human Immunodeficiency Virus-Mycobacterium tuberculosis Co-Infection. J Clin Med. 2020 Nov;9(11):3575.
5. Deeks SG, Lewin SR, Havlir DV. The End of AIDS: HIV Infection as a Chronic Disease. Lancet. 2013 Nov 2;382(9903):1525–33.
6. Chun TW, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol. 2015 Jun;16(6):584–9.
7. Ndung’u T, McCune JM, Deeks SG. Why and where an HIV cure is needed and how it might be achieved. Nature. 2019 Dec;576(7787):397–405.
8. Chun TW, Eisinger RW, Fauci AS. Durable Control of HIV Infection in the Absence of Antiretroviral Therapy: Opportunities and Obstacles. JAMA. 2019 Jul 2;322(1):27–8.
9. Rai MA, Chun T. Combination anti‐HIV antibodies to achieve antiretroviral therapy‐free virological suppression in infected individuals. Clin Transl Med. 2022 Sep 13;12(9):e1057.
10. Kumar D, Gauthami S, Bayry J, Kaveri SV, Hegde NR. Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond. Monoclon Antibodies Immunodiagn Immunother. 2021 Apr;40(2):36–49.
11. Walker LM, Burton DR. Passive immunotherapy of viral infections: “super-antibodies” enter the fray. Nat Rev Immunol. 2018 May;18(5):297–308.
12. Walsh SR, Seaman MS. Broadly Neutralizing Antibodies for HIV-1 Prevention. Front Immunol [Internet]. 2021 Jul 20 [cited 2024 Jul 5];12. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.712122/full
13. Zhang Z, Li S, Gu Y, Xia N. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies. Int J Mol Sci. 2016 Nov 18;17(11):1901.
14. Gils MJ van, Sanders RW. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology. 2013 Jan 5;435(1):46–56.
15. Caskey M, Klein F, Nussenzweig MC. Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. Nat Med. 2019 Apr;25(4):547–53.
16. Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020 Mar 19;382(12):1112–23.
17. Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018 Sep;561(7724):479–84.
18. Nishimura Y, Gautam R, Chun TW, Sadjadpour R, Foulds KE, Shingai M, et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017 Mar 23;543(7646):559–63.
19. Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JCC, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016 Jul 28;535(7613):556–60.
20. Julg B, Stephenson KE, Wagh K, Tan SC, Zash R, Walsh S, et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat Med. 2022;28(6):1288–96.
21. Sneller MC, Blazkova J, Justement JS, Shi V, Kennedy BD, Gittens K, et al. Combination anti-HIV antibodies provide sustained virologic suppression. Nature. 2022 Jun;606(7913):375–81.
22. Kumar S, Singh S, Luthra K. An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1. ACS Omega. 2023 Feb 15;8(8):7252–61.
23. Stephenson KE, Barouch DH. Broadly Neutralizing Antibodies for HIV Eradication. Curr HIV/AIDS Rep. 2016;13:31–7.
24. Griffith SA, McCoy LE. To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. Front Immunol. 2021 Oct 19;12:708227.
25. Wang H, Gristick HB, Scharf L, West AP, Galimidi RP, Seaman MS, et al. Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. eLife. 2017;6:e27389.
26. McCoy LE, McKnight Á. Lessons learned from humoral responses of HIV patients. Curr Opin HIV AIDS. 2017 May;12(3):195–202.
27. West AP, Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell. 2014 Feb 13;156(4):633–48.
28. Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015 Oct;67(2 Pt A):171–82.
29. Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun. 2016 Mar 3;7(1):10844.
30. Thavarajah JJ, Hønge BL, Wejse CM. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention. Viruses. 2024 Jun;16(6):911.
31. Gama L, Koup RA. New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment. Annu Rev Med. 2018 Jan 29;69:409–19.
32. Hou W, Fang C, Liu J, Yu H, Qi J, Zhang Z, et al. Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody. Antiviral Res. 2015 Oct;122:101–11.
33. Pace CS, Fordyce MW, Franco D, Kao CY, Seaman MS, Ho DD. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr 1999. 2013 Jan 1;62(1):1–9.
34. Lu CL, Murakowski DK, Bournazos S, Schoofs T, Sarkar D, Halper-Stromberg A, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science. 2016 May 20;352(6288):1001–4.
35. Pegu A, Yang Z yong, Boyington JC, Wu L, Ko SY, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014 Jul 2;6(243):243ra88.
36. Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med. 2016 Nov 24;375(21):2037–50.
37. Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol. 2015 Mar;89(5):2659–71.
38. Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, et al. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. Cell Host Microbe. 2019 Jan 9;25(1):59-72.e8.
39. Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, et al. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. J Virol. 2016 Jan 1;90(1):76–91.
40. Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, et al. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLOS Pathog. 2016 Mar 30;12(3):e1005520.
41. Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, et al. Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018 Nov;24(11):1701–7.
42. Gaebler C, Nogueira L, Stoffel E, Oliveira TY, Breton G, Millard KG, et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature. 2022 Jun;606(7913):368–74.
43. Shapiro RL, Ajibola G, Maswabi K, Hughes M, Nelson BS, Niesar A, et al. Broadly Neutralizing Antibody Treatment Maintained HIV Suppression in Children with Favorable Reservoir Characteristics in Botswana. Sci Transl Med. 2023 Jul 5;15(703):eadh0004.
44. Eron JJ, Little SJ, Crofoot G, Cook P, Ruane PJ, Jayaweera D, et al. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Lancet HIV. 2024 Mar;11(3):e146–55.
45. Lorenzi JCC, Cohen YZ, Cohn LB, Kreider EF, Barton JP, Learn GH, et al. Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):E7908–16.
46. Hake A, Pfeifer N. Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time. PLOS Comput Biol. 2017 Oct 24;13(10):e1005789.
47. Magaret CA, Benkeser DC, Williamson BD, Borate BR, Carpp LN, Georgiev IS, et al. Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. PLoS Comput Biol. 2019 Apr;15(4):e1006952.
48. Kerwin BA, Bennett C, Brodsky Y, Clark R, Floyd JA, Gillespie A, et al. Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity. J Pharm Sci. 2020 Jan;109(1):233–46.
49. Patel A, Gupta V, Hickey J, Nightlinger NS, Rogers RS, Siska C, et al. Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies. J Pharm Sci. 2018 Dec;107(12):3032–46.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 JIMKI: Jurnal Ilmiah Mahasiswa Kedokteran Indonesia
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.